Interstitial lung disease

AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis

Retrieved on: 
Monday, February 5, 2024
Inflammation, Systemic scleroderma, Biomarker, Patient, Diagnosis, FDA, EMA, Marketing, Scleroderma, Interstitial lung disease, Skin, Pulmonary fibrosis, Disability, Disease, Fibrosis, European Medicines Agency, Death, ODD, Autoimmune disease, ILD, Organ dysfunction, Pharmaceutical industry

AM1476 offers a unique dual-action approach to treat both skin and lung manifestations of systemic sclerosis.

Key Points: 
  • AM1476 offers a unique dual-action approach to treat both skin and lung manifestations of systemic sclerosis.
  • Systemic sclerosis is a chronic, progressive, autoimmune disease characterized by inflammation and fibrosis, i.e.
  • AnaMar's Chief Executive Officer, Dr. Ulf Ljungberg, said: “We are delighted with the FDA’s and EMA’s decisions to grant orphan drug designation to AM1476 for SSc.
  • Orphan drug designation provides certain benefits, including the potential for extensive marketing exclusivity following regulatory approval, reduction in regulatory fees and, in the case of EU, a centralized approval process.

New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease

Retrieved on: 
Thursday, October 12, 2023
Health, Genetics, Clinical Trials, General Health, Cardiology, Biotechnology, Annual general meeting, Diagnosis, UIP, Physician, American College of Chest Physicians, Radiology, American College, ILD, Connective tissue, Idiopathic pulmonary fibrosis, HRCT, UCLA Health, CT, Vicki Belo, Interstitial lung disease, Scar, Disorder, Fibrosis, Patient, Medical imaging, Medical device, Pulmonology

(Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 demonstrate the clinical utility of the company’s Envisia Genomic Classifier, which is used by physicians to improve diagnostic and prognostic confidence of interstitial lung diseases (ILDs).

Key Points: 
  • (Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 demonstrate the clinical utility of the company’s Envisia Genomic Classifier, which is used by physicians to improve diagnostic and prognostic confidence of interstitial lung diseases (ILDs).
  • The studies also underscore the challenge of identifying usual interstitial pneumonia (UIP) in patients being evaluated for ILD.
  • The studies presented at the CHEST Annual Meeting show that adding the Envisia Genomic Classifier to the diagnostic process can improve the ability to detect UIP.
  • For patients with indeterminate HRCT results, adding the Envisia Genomic Classifier more than doubled the UIP diagnostic yield to 49%.

ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Retrieved on: 
Thursday, July 27, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Progression-free survival, HER2, Survival, ILD, Medicine, Interstitial lung disease, AstraZeneca, PFS, ASCO, Dor, MD, Patient, Daiichi Sankyo, Cancer, ADC, Biliary tract, Society, ORR, Safety, Medical imaging

Topline results from the primary analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2 expressing advanced solid tumors, two secondary endpoints of the trial.

Key Points: 
  • Topline results from the primary analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2 expressing advanced solid tumors, two secondary endpoints of the trial.
  • ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • The DESTINY-PanTumor02 phase 2 trial is evaluating the efficacy and safety of ENHERTU in patients with previously treated locally advanced, unresectable or metastatic HER2 expressing solid tumors not eligible for curative therapy, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic and other cancers.
  • These data will be presented at an upcoming medical meeting and will support ongoing discussions with global health authorities.

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Wednesday, June 21, 2023
Sarcoidosis, TSC2, Myelocyte, Heart, Mouse, Granuloma, Cleveland Clinic, MOUSE, OH, Medical school, CARDIAC, Fibroblast, Medical University of Vienna, Pulmonology, Fibrosis, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Vicki Belo, Interstitial lung disease, Extracellular matrix, Biology, Matrix, Poster, Cleveland, Conference, Disease, Vaccine, Pharmaceutical industry, Medical device, Genetics, Foresight

MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.

Key Points: 
  • MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.
  • The role of MMP-12 and its therapeutic implications may extend to other aspects of sarcoidosis and interstitial lung diseases.
  • TAIPEI, June 21, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company and its collaborators presented a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • Fibrotic collagen deposition was significantly reduced, as well as the total number of activated fibroblasts in the whole heart.

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Wednesday, June 21, 2023
Sarcoidosis, TSC2, Myelocyte, Heart, Mouse, Granuloma, Cleveland Clinic, MOUSE, OH, Medical school, CARDIAC, Fibroblast, Medical University of Vienna, Pulmonology, Fibrosis, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Vicki Belo, Interstitial lung disease, Extracellular matrix, Biology, Matrix, Poster, Cleveland, Conference, Disease, Vaccine, Pharmaceutical industry, Medical device, Genetics, Foresight

MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.

Key Points: 
  • MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.
  • The role of MMP-12 and its therapeutic implications may extend to other aspects of sarcoidosis and interstitial lung diseases.
  • TAIPEI, June 21, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company and its collaborators presented a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • Fibrotic collagen deposition was significantly reduced, as well as the total number of activated fibroblasts in the whole heart.

FORESEE PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AND PARTICIPATION AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Friday, June 16, 2023
Sarcoidosis, MOUSE, Asthma, CARDIAC, Biomarker, Foresight, International Conference on Emerging Infectious Diseases, Poster, Patient, Interstitial lung disease, Vicki Belo, IND, Conference, Pharmaceutical industry

TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.

Key Points: 
  • Poster on FP-020, a follow-on, best-in-class, oral MMP-12 inhibitor in a genetic model of sarcoidosis includes efficacy, biomarkers and complete translational cellular profiling supporting novel anti-inflammatory and anti-fibrotic mechanism
    TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • "We are very excited to have the opportunity to present such compelling data related to FP-020 in this sarcoidosis model.
  • The data strongly supports the role of MMP-12 in sarcoidosis disease biology and further strengthens our view on the promise of our MMP-12 inhibitors for sarcoidosis and ILDs" said Dr. Wenjin Yang, Chief Scientific Officer at Foresee.
  • The poster will be available to view during the WASOG conference, Tuesday June 20, 2023 and available after the conference.

FORESEE PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AND PARTICIPATION AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Friday, June 16, 2023
Sarcoidosis, MOUSE, Asthma, CARDIAC, Biomarker, Foresight, International Conference on Emerging Infectious Diseases, Poster, Patient, Interstitial lung disease, Vicki Belo, IND, Conference, Pharmaceutical industry

TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.

Key Points: 
  • Poster on FP-020, a follow-on, best-in-class, oral MMP-12 inhibitor in a genetic model of sarcoidosis includes efficacy, biomarkers and complete translational cellular profiling supporting novel anti-inflammatory and anti-fibrotic mechanism
    TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • "We are very excited to have the opportunity to present such compelling data related to FP-020 in this sarcoidosis model.
  • The data strongly supports the role of MMP-12 in sarcoidosis disease biology and further strengthens our view on the promise of our MMP-12 inhibitors for sarcoidosis and ILDs" said Dr. Wenjin Yang, Chief Scientific Officer at Foresee.
  • The poster will be available to view during the WASOG conference, Tuesday June 20, 2023 and available after the conference.

AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis

Retrieved on: 
Tuesday, May 23, 2023
Therapy, Disability, ILD, Organ dysfunction, Biomarker, Scleroderma, Interstitial lung disease, Lung, EMA, Fibrosis, Vital capacity, Patient, CGMP, FDA, Death, Systemic scleroderma, Skin, Disease, Pharmaceutical industry, Research

LUND, Sweden, May 23, 2023 (GLOBE NEWSWIRE) -- AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, announces positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis (SSc) characterized by lung and skin fibrosis.

Key Points: 
  • Skin fibrosis is a leading feature of SSc associated with significant disability.
  • The degree of skin fibrosis provides insight about progression of the disease.
  • Active product ingredients are being made ready as cGMP materials for this Phase II trial.
  • The company is planning regulatory submissions, in 2023, to the FDA and EMA for Orphan Drug Designation for the rare disease SSc.

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Retrieved on: 
Wednesday, May 24, 2023
Oncology, Health, Health Technology, Genetics, Other Health, Clinical Trials, Biotechnology, CT, Lung nodule, University, HRCT, ATS, University of Washington Medical Center, UIP, Cancer, Lung cancer, ILD, FVC, American Thoracic Society, Interstitial lung disease, Restrictive lung disease, Vital capacity, Patient, Physician, Risk, Vicki Belo, Diagnosis, IPF, Massachusetts General Hospital, Idiopathic pulmonary fibrosis, Medical device, Pharmaceutical industry, Medical imaging

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer.
  • The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C.
  • For Veracyte’s Percepta Nasal Swab, researchers presented updated preliminary study findings showing the test’s potential to better stratify the risk of lung cancer for patients with lung nodules.
  • “Importantly, these findings suggest that our tests in interstitial lung disease and lung cancer are performing as intended.”

IMVARIA Announces Data Demonstrating Company’s Non-Invasive Digital Biomarker for Predicting Mortality in Interstitial Lung Diseases

Retrieved on: 
Thursday, May 18, 2023
Research, Technology, Health Technology, Nanotechnology, Software, General Health, Health, Data Management, Science, Artificial Intelligence, CT, Idiopathic disease, Mini, Idiopathic pulmonary fibrosis, Disability, ATS, DC, ILD, Prognosis, Crystal ball, FVC, Mortality, Gender, American Thoracic Society, GAP, Biomarker, Food and Drug Administration Amendments Act of 2007, Vital capacity, International Conference on Information Systems Security and Privacy, MD, Patient, Physician, Risk, Interstitial lung disease, Diagnosis, FDA, IPF, Death, Conference, Food, Medical imaging, Medical device, Physiology

IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced data from a study evaluating the company’s lead non-invasive digital biomarker Fibresolve showing the tool’s supplemental ability to predict mortality in patients with interstitial lung disease (ILD).

Key Points: 
  • IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced data from a study evaluating the company’s lead non-invasive digital biomarker Fibresolve showing the tool’s supplemental ability to predict mortality in patients with interstitial lung disease (ILD).
  • Interstitial lung diseases are a group of lung diseases characterized by progressive scarring of lung tissue that causes progressive difficulty in breathing and early death, particularly if untreated.
  • Standard diagnosis is done with CT scan along with lung function testing, which is evaluated through measuring lung volumes.
  • The company also announced three additional poster presentations at ATS 2023 demonstrating the development and utility of Fibresolve.